Drugs

Drug name
Clinical area
Regulatory class
Research status
Patent status

Projects in the registration phase

MTC-A4
Clinical area: Neurology
Regulatory class: Drug with increased bioavailability
Research status: Pre-clinical tests
Patent status: Patent application
MTC-U1
Clinical area: Tissue regeneration
Regulatory class: Biosimilar drug
Research status: Pre-clinical tests
Patent status: Patent application
CRP-21
Clinical area: Multi-systemic tick-borne infections
Regulatory class: Biosimilar drug
Research status: Pre-clinical tests
Patent status: Patent application

Projects in the laboratory testing phase

MTC-B7
Clinical area: Oncology
Regulatory class: Biosimilar drug
Research status: Laboratory tests
Patent status: In progress
MTC-R2
Clinical area: Oncology
Regulatory class: Biosimilar drug
Research status: Laboratory tests
Patent status: In progress
MTC-S1
Clinical area: Oncology
Regulatory class: Biosimilar drug
Research status: Laboratory tests
Patent status: In progress

MTC-A4

The MTC-A4 mixture is an original topical anesthetic offering an increased bioavailability and permeability through skin layers. Thanks to the technology used in MTC-A4, it is possible to target the action of topical anesthetics on nerve endings located in the spinous layer of the skin and nerves in the dermis. The effect of the applied MTC-A4 solutions offers about 10 times stronger local action compared to anesthetics available on the market.

Basic research Pre-clinical tests Phase I Phase II

MTC-U1

The MTC-U1 mixture is an original drug for the treatment of bedsores and ulcers of the lower extremities. With the therapeutic system thus developed it is possible to inhibit inflammatory conditions, stop local development of infections and support natural tissue regeneration processes. The MTC-U1 mixture is based on natural active substances, a multiphase, semi-solid form of the drug with an increased bioavailability and a modified release profile. The result of the solutions applied is a cheaply produced anti-inflammatory preparation, accelerating the regeneration of healthy tissues and having a wide range of applications, e.g. on skin inflammations, ulcers, decubitus ulcers, and wounds that are difficult to heal.

Basic research Pre-clinical tests Phase I Phase II

CRP-21

CRP-21 is an original formula of a drug, which can be used to treat infections caused by intracellular bacteria. The main application of the therapeutic system is the treatment of various types of tick-borne diseases. CRP-21 is an easily assimilated mixture of active substances from the polyphenols group. A unique multistage extraction technology has made it possible to obtain active substances in the form of natural bio-complexes with an increased bioavailability. The use of a unique mixture of solvents used in the extraction also allowed us to create a preparation with an increased effect on the cellular structures of pathogens.

Basic research Pre-clinical tests Phase I Phase II

MTC-B7

The MTC-B7 mixture supporting breast cancer treatment was created on the basis of the transdermal therapeutic system MTC-Y enriched with natural absorption promoters and extracts of active substances. Thanks to the simultaneous application of the deep penetrating transdermal system and specific, selective absorption promoters, it is possible to transport active substances inhibiting the proliferation of pathologically changed tissues. As a result of technological solutions applied, a preparation has been created that softens solid tumour tissues, at the same time sensitizing them to the action of anticancer substances.

Basic research Pre-clinical tests Phase I Phase II

MTC-R2

The MTC-R2 mixture supporting treatment of rectal cancer was created on the basis of the transdermal therapeutic system MTC-Y enriched with natural absorption promoters and therapeutic substances. Thanks to the simultaneous application of the deep penetrating transdermal system and specific, selective absorption promoters, it is possible to transport active substances inhibiting the proliferation of pathologically changed tissues. As a result of technological solutions applied, a preparation has been created that softens solid tumour tissues, at the same time sensitizing them to the action of anticancer substances.

Basic research Pre-clinical tests Phase I Phase II

MTC-S1

The MTC-S1 mixture is a therapeutic system supporting the treatment of skin cancer created on the basis of a unique formula of synergistically acting active substances and a system of promoters, thanks to which it is possible to selectively act on skin tissue tumours. The technological solutions applied have made it possible to obtain a preparation softening tumour tissues and sensitizing tumour cells to the action of active substances.

Basic research Pre-clinical tests Phase I Phase II